ABEO (Abeona Therapeutics) 10-Year Share Buyback Ratio : -47.10% (As of Dec. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Abeona Therapeutics's current 10-Year Share Buyback Ratio was -47.10%.

ABEO's 10-Year Share Buyback Ratio is ranked worse than
84.23% of 647 companies
in the Biotechnology industry
Industry Median: -12.6 vs ABEO: -47.10

Competitive Comparison of Abeona Therapeutics's 10-Year Share Buyback Ratio

For the Biotechnology subindustry, Abeona Therapeutics's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abeona Therapeutics's 10-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's 10-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Abeona Therapeutics 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Abeona Therapeutics (NAS:ABEO) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Abeona Therapeutics 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Abeona Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » 10-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

0H7R:UK PCJ:Germany PCJ:Germany

Address

6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103

Website

https://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Executives

Vishwas Seshadri	director, officer: Chief Executive Officer	64 STRYKER COURT, BRIDGEWATER NJ 08807
Mark Alvino	director	C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Christine Berni Silverstein	officer: Chief Financial Officer	C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Leila Alland	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Brendan M. O'malley	officer: SVP, General Counsel	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano	officer: Chief Financial Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Michael Amoroso	officer: Chief Operating Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c.	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr	officer: Vice President, Controller	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider	director	4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219